CYDY - CytoDyn to conduct two COVID-19 trials in Brazil

CytoDyn (CYDY) announces an agreement to partner with Academic Research Organization - Albert Einstein Israelite Hospital in São Paulo, Brazil for two COVID-19 trials. The COVID-19 trials in Brazil are intended to provide the regulatory authority, ANVISA, with the requisite data to consider advancing the availability of leronlimab to thousands of local citizens infected with COVID-19. These two Phase 3 trials will be conducted in up to 45 clinical sites. "With approximately 1,500 patients in total for both trials, we anticipate having adequate power in each trial to achieve a significant p-value for our endpoints and will be performing an interim analysis after 40% of the critically ill patients are enrolled,” commented Chris Recknor, M.D., CytoDyn’s Chief Operating Officer and Head of Clinical Development.Recently, the company provided an update on leronlimab HIV extension arm.

For further details see:

CytoDyn to conduct two COVID-19 trials in Brazil